Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy

Urologia Internationalis

Volumn 79, Issue 4, 2007, Pages 356-360

  Shimizu, Fumitaka ^a   Matsuyama, Yutaka ^b   Tominaga, Takashi ^c   Ohashi, Yasuo ^b   Fujime, Makoto ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Biochemical recurrence; Linear models; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Ultrasensitive assay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; AMPLIFIER; ARTICLE; CHEMICAL ANALYSIS; CHI SQUARE TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL ASSAY; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 36248937132     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109723     Document Type: Article

References (15)

1. Han M, Partin AW, Piantadosi S, et al: Eraspecific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-419.
2. Hull GW, Rabbani F, Abbas F, et al: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
3. Ornstein DK, Colberg JW, Virgo KS, et al: Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 1998;52:1047-1054.
4. Cox JD, Gallagher MJ, Hammond EH, et al: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155-1163.
5. Ward JF, Zincke H, Bergstralh EJ, et al: Prostate-specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244-2248.
6. Cheung R, Kamat AM, de Crevoisier R, et al: Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63:134-140.
7. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
8. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate-specific antigen doubling times and log slope prostate-specific antigen. J Urol 1997;158:1441-1445.
9. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030-1039.
10. Prostate Cancer End Points Workshop Presentations, vol 2004. Available at: http://www.fda.gov/cder/drug/cancer_endpoints/ProstatePresent/default.htm. Accessed: 12 January 2007.
11. Yu H, Diamandis EP, Wong PY, et al: Detection of prostate cancer relapse with prostate-specific antigen monitoring at levels of 0.001 to 0.1 μg/l. J Urol 1997;157:913-918.
12. Shen S, Lepor H, Yaffee R, et al: Ultrasensitive serum prostate-specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777-780.
13. Hayashi A: Clinical utility of the ultrasensitive prostate-specific antigen assay 'Immulyze HS-PSA'. J Anal Biosci 2004;27:284-290.
14. Soergel TM, Koch MO, Foster RS, et al: Accuracy of predicting long-term prostate-specific antigen outcome based on early prostate-specific antigen recurrence results after radical prostatectomy. J Urol 2001;166:2198-2201.
15. Ross PL, Mahmud S, Stephenson AJ, et al: Variations in PSA doubling time in patients with prostate cancer on 'watchful waiting': value of short-term PSADT determinations. Urology 2004;64:323-328.